Idorsia H1 FY26 net loss widens to CHF 153 million; net sales climb 62% to CHF 91 million

(AWP Alliance News) - Idorsia posted a US GAAP net loss of CHF 153 million for H1 2026, swinging from a net profit a year earlier, while net revenue fell to CHF 110 million from the prior-year period. QUVIVIQ net sales climbed 62% year-on-year to CHF 91 million, supporting the group's focus on expanding access and geographic reach for the insomnia drug.

US GAAP operating loss widened to CHF 63 million as operating expenses rose to CHF 174 million. The company reaffirmed its full-year 2026 guidance for QUVIVIQ net sales of CHF 200 million, non-GAAP operating expenses of about CHF 330 million, and a non-GAAP operating loss of about CHF 120 million.

https://www.publicnow.com/view/E799EEFD4497EC93BE87E8BE426C74B65AF73CEC…

Disclaimer: This news brief was created using generative artificial intelligence. Idorsia Ltd. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.